Cambridge Epigenetix

Cambridge Epigenetix, now known as Biomodal, is a unique biotechnological company specializing in the exploration of biology in all its dimensions. The company is the leading player in advancing our understanding of epigenetics, rising in the medical field on a global scale. With a hands-on approach and a comprehensive portfolio of technologies, they aim to unravel the complexities of genetic and epigenetic information simultaneously, creating a tangible impact on the realm of normal and disease biology.

The central facet of Biomodal's operation is its pioneering tech-endeavor that expands the potential of DNA information gain. The company has developed solutions that overcome the limitations of current technologies in resolving both genetic and epigenetic sequences simultaneously. They deliver accurate multiomic analysis, collecting numerous modalities in a single workflow requiring only minimal DNA samples. Their various applications in cancer research, aging, population genetics, non-invasive prenatal testing, neurodegenerative disease studies, and precision medicine showcase an expansive range of possibilities for their cutting-edge technology.

Biomodal, previously Cambridge Epigenetix, stands out as a company that thrives on curiosity and innovation, exploring uncharted territories in the biological sciences. They offer a transformative multiomics solution, introducing 'duet', which combines genetic and epigenetic sequence data from a single sample. The company is a key player in developing potential therapeutic targets for diseases such as Alzheimer's and is an important partner for anyone interested in the medical application of epigenetic and genetic research. Therefore, being abreast with Biomodal's developments means staying informed about a critical frontier in the realm of bio-technology.

Connect